Haddock David 4

What Happened
David Haddock, EVP, General Counsel & Corporate Secretary of Pediatrix Medical Group (MD), received two equity awards on 2026-06-22: 20,036 restricted shares (granted at $0.00) and 51,000 performance share units (PSUs, derivative award, granted at $0.00). The restricted shares are ordinary time‑based awards that vest over three years; the PSUs are contingent on both service and performance and may convert to common shares if performance hurdles are met.

Key Details

• Transaction date: 2026-06-22; Form 4 filed 2026-06-24 (timely filing).
• Consideration/price: $0.00 for both grants (compensation awards, not purchases).
• Restricted shares granted: 20,036; PSUs granted (derivative): 51,000.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnote F1 (restricted shares): Vesting — 25% on 6/1/2027, 25% on 6/1/2028, 50% on 6/1/2029, subject to plan terms.
• Footnote F2 (PSUs): Each PSU is a contingent right to one share; PSUs vest to the extent earned on the 3‑year anniversary, with earn‑outs in one‑third increments tied to achieving stock price hurdles equal to 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days prior to the vesting date.

Context
These awards are compensation grants (A = Award/Grant) rather than open‑market purchases or sales; they carry service and performance conditions and do not involve immediate cash payment or sale. PSUs are derivative, contingent awards that only convert to shares if the specified performance and service conditions are met. Such grants are routine elements of executive pay and should not be interpreted by themselves as a direct buy/sell signal.